Hemodynamic and therapeutic effect of BAY a 1040 on the patients with ischemic heart disease.
D000293:Adolescent; D000328:Adult; D000368:Aged; D000787:Angina Pectoris / Q000188:drug therapy*; D001794:Blood Pressure / Q000187:drug effects; D002302:Cardiac Output / Q000187:drug effects; D002986:Clinical Trials as Topic; D003327:Coronary Disease / Q000188:drug therapy; D003331:Coronary Vessels / Q000187:drug effects; D003998:Dicarboxylic Acids / Q000494:pharmacology / Q000627:therapeutic use; D004562:Electrocardiography; D005260:Female; D006321:Heart / Q000187:drug effects; D006339:Heart Rate / Q000187:drug effects; D006801:Humans; D008297:Male; D008875:Middle Aged; D009578:Nitrobenzenes / Q000494:pharmacology / Q000627:therapeutic use*; D010919:Placebos; D011725:Pyridines / Q000494:pharmacology / Q000627:therapeutic use*; D014655:Vascular Resistance / Q000187:drug effects; D014665:Vasodilator Agents / Q000494:pharmacology / Q000627:therapeutic use*
D003998:Dicarboxylic Acids; D009578:Nitrobenzenes; D010919:Placebos; D011725:Pyridines; D014665:Vasodilator Agents